Arca
Skip to content
Tools
Tools

Menopause

Drug research and approvals for menopause: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 178 studies of menopause are recruiting on ClinicalTrials.gov, Health Canada has authorized 6 drug trials for it since 2013, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 178
  • Trials authorized in Canada: 6
  • FDA orphan approvals: 0
  • EU medicines: 2

Recruiting Now

Newest start dates first, of 178 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

9 approved, 20 in phase 3, 11 in phase 2, 9 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Estrogens, conjugated, Estrogens, esterified, Estradiol valerate, Paroxetine, Synthetic conjugated estrogens, b, Estradiol acetate, Estrogens, conjugated synthetic a, Estrone sulfuric acid, Ospemifene

Progesterone
Phase 3 Progesterone receptor agonist
Bazedoxifene
Phase 3 Estrogen receptor modulator
Medroxyprogesterone acetate
Phase 3 Progesterone receptor agonist
Isoflavone
Phase 3
Desvenlafaxine
Phase 3 Serotonin transporter inhibitor
Dydrogesterone
Phase 3 Progesterone receptor agonist
Elinzanetant
Phase 3 Neurokinin 1 receptor antagonist
Testosterone
Phase 3 Androgen Receptor agonist
Tibolone
Phase 3
Tamoxifen
Phase 3 Estrogen receptor alpha modulator
Norethindrone acetate
Phase 3 Progesterone receptor agonist
Prasterone
Phase 3 Unknown
Calcitonin salmon
Phase 3 Calcitonin receptor agonist
Goserelin
Phase 3 Gonadotropin-releasing hormone receptor agonist
Ergocalciferol
Phase 3 Vitamin D receptor agonist
Letrozole
Phase 3 Cytochrome P450 19A1 inhibitor
Cyclophosphamide anhydrous
Phase 3 DNA inhibitor
Ascorbic acid
Phase 3 Supplement
Vitamin e
Phase 3
Methyltestosterone
Phase 2 Androgen Receptor agonist
Estriol
Phase 2 Estrogen receptor modulator
Raloxifene
Phase 2 Estrogen receptor beta modulator
Risedronic acid
Phase 2 Farnesyl diphosphate synthase inhibitor
AUS-131
Phase 2 Estrogen receptor beta agonist
MF101
Phase 2 Estrogen receptor beta agonist
Asoprisnil
Phase 2 Progesterone receptor modulator
SMC021
Phase 2 Calcitonin receptor agonist
Melatonin
Phase 2 Melatonin receptor agonist

Showing the 30 furthest along of 40 in trials.

Trials Authorized in Canada

Newest first; search them all in Canada trials
Jul 28, 2021A phase 3b, randomized, double-blind, placebo-controlled, 24-week study to assess the efficacy and safety of fezolinetant in menopausal women suffering from…Fezolinetant (ESN364)Astellas PharmaClosed
Sep 30, 2020A randomized double-blind placebo controlled phase 3 trial to evaluate the efficacy and safety of estetrol for the treatment of moderate to severe vasomotor…estetrol/ progesteroneEstetra SrlClosed
Sep 27, 2019A randomized double-blind placebo controlled phase 3 trial to evaluate the efficacy and safety of estetrol for the treatment of moderate to severe vasomotor…EstetrolEstetra SprlClosed
Jul 5, 2019A phase 3, randomized, placebo-controlled, 12-week double-blind study, followed by a non-controlled extension treatment period, to assess the efficacy and…FezolinetantAstellas PharmaClosed
Jul 5, 2019A phase 3 randomized, placebo-controlled, 12-week double-blind study, followed by a non-controlled extension treatment period, to assess the efficacy and…FezolinetantAstellas PharmaClosed
Apr 25, 2019A randomized, placebo-controlled, double-blind phase 3 clinical study to investigate the long-term safety of fezolinetant in women suffering from vasomotor…FezolinetantAstellas PharmaClosed

Medicines Authorised in the EU

Newest first
Mar 26, 2026FylrevyEstetrolGedeon Richter Plc.EMA ↗
Dec 7, 2023VeozaFezolinetantAstellas Pharma Europe B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.